Intercept Pharmaceuticals (ICPT) Target Raised to $270 at BMO Capital

January 9, 2014 10:00 AM EST Send to a Friend
BMO Capital maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login